Literature DB >> 17013881

Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.

Sharon D Morgenbesser1, Rajashree P McLaren, Brenda Richards, Mindy Zhang, Viatcheslav R Akmaev, Scott F Winter, Nora D Mineva, Paula J Kaplan-Lefko, Barbara A Foster, Brian P Cook, Michael R Dufault, Xiahong Cao, Clarence J Wang, Beverly A Teicher, Katherine W Klinger, Norman M Greenberg, Stephen L Madden.   

Abstract

BACKGROUND: A major focus of prostate cancer research has been to identify genes that are deregulated during tumor progression, potentially providing diagnostic markers and therapeutic targets.
METHODS: We have employed serial analysis of gene expression (SAGE) and microarray hybridization to identify alterations that occur during malignant transformation in the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model. Many of these alterations were validated by real-time PCR (rtPCR).
RESULTS: We identified several hundred mRNAs that were deregulated. Cluster analysis of microarray profiles with samples from various stages of the disease demonstrated that androgen-independent (AI) primary tumors are similar to metastases; 180 transcripts have expression patterns suggesting an involvement in the genesis of late-stage tumors, and our data support a role for phospholipase A2 group IIA in the acquisition of their highly aggressive characteristics.
CONCLUSIONS: Our analyses identified well-characterized genes that were previously known to be involved in prostate cancer, validating our study, and also uncovered transcripts that had not previously been implicated in prostate cancer progression. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17013881     DOI: 10.1002/pros.20505

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

1.  Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.

Authors:  Leslie Oleksowicz; Yin Liu; R Bruce Bracken; Krishnanath Gaitonde; Barbara Burke; Paul Succop; Linda Levin; Zhongyun Dong; Shan Lu
Journal:  Prostate       Date:  2011-11-29       Impact factor: 4.104

2.  Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.

Authors:  Mario Menschikowski; Albert Hagelgans; Eugene Gussakovsky; Heike Kostka; Elena L Paley; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

Review 3.  Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.

Authors:  Giuseppe Colloca; Antonella Venturino; Franco Checcaglini
Journal:  Med Oncol       Date:  2011-02-20       Impact factor: 3.064

4.  Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations.

Authors:  Junxuan Lü; Jinhui Zhang; Li Li; Cheng Jiang; Chengguo Xing
Journal:  Curr Pharmacol Rep       Date:  2015-04-19

5.  Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.

Authors:  Zhongyun Dong; Yin Liu; Kieran F Scott; Linda Levin; Krishnanath Gaitonde; R Bruce Bracken; Barbara Burke; Qihui Jim Zhai; Jiang Wang; Leslie Oleksowicz; Shan Lu
Journal:  Carcinogenesis       Date:  2010-09-13       Impact factor: 4.944

6.  LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.

Authors:  Tammy L Romanuik; Gang Wang; Olena Morozova; Allen Delaney; Marco A Marra; Marianne D Sadar
Journal:  BMC Med Genomics       Date:  2010-09-24       Impact factor: 3.063

7.  Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.

Authors:  Mario Menschikowski; Albert Hagelgans; Ulrich Schuler; Susanne Froeschke; Andrea Rosner; Gabriele Siegert
Journal:  Pathol Oncol Res       Date:  2013-06-01       Impact factor: 3.201

8.  Chemopreventive effect of Korean Angelica root extract on TRAMP carcinogenesis and integrative "omic" profiling of affected neuroendocrine carcinomas.

Authors:  Jinhui Zhang; Lei Wang; Yong Zhang; Li Li; Suni Tang; Chengguo Xing; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Mol Carcinog       Date:  2014-10-12       Impact factor: 4.784

9.  Evolution of the vertebrate paralemmin gene family: ancient origin of gene duplicates suggests distinct functions.

Authors:  Greta Hultqvist; Daniel Ocampo Daza; Dan Larhammar; Manfred W Kilimann
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers.

Authors:  Casey M Turk; Katerina D Fagan-Solis; Kristin E Williams; Joseph M Gozgit; Sallie Smith-Schneider; Sharon A Marconi; Christopher N Otis; Giovanna M Crisi; Douglas L Anderton; Manfred W Kilimann; Kathleen F Arcaro
Journal:  Cancer Cell Int       Date:  2012-05-10       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.